300636 同和药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.0855.9779.1199.5189.200
总资产报酬率 ROA (%)2.1233.8684.8334.8085.642
投入资产回报率 ROIC (%)2.1934.0835.2595.1165.974

边际利润分析
销售毛利率 (%)34.52833.30132.42830.20634.944
营业利润率 (%)20.20915.54214.77014.91917.971
息税前利润/营业总收入 (%)17.40414.27715.81215.48720.241
净利润/营业总收入 (%)18.20514.67613.98313.70016.088

收益指标分析
经营活动净收益/利润总额(%)112.629108.657104.621105.10994.981
价值变动净收益/利润总额(%)-0.0590.505-1.1390.3120.087
营业外收支净额/利润总额(%)-0.0870.238-0.1720.000-0.243

偿债能力分析
流动比率 (X)2.1051.7061.3181.7842.577
速动比率 (X)1.2270.9600.4530.7491.278
资产负债率 (%)31.47330.88741.57853.4220.444
带息债务/全部投入资本 (%)27.72527.16534.57147.16340.485
股东权益/带息债务 (%)255.100263.003183.985107.399142.223
股东权益/负债合计 (%)217.730223.766140.51287.188125.390
利息保障倍数 (X)-6.244-10.97014.81227.2648.750

营运能力分析
应收账款周转天数 (天)42.22039.53336.87424.07936.723
存货周转天数 (天)377.603381.473322.210308.733365.721